Biocure Technology (XCNQ:CURE) Total Liabilities : C$0.44 Mil (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Total Liabilities?

Biocure Technology's Total Liabilities for the quarter that ended in Sep. 2024 was C$0.44 Mil.

Biocure Technology's quarterly Total Liabilities increased from Mar. 2024 (C$0.40 Mil) to Jun. 2024 (C$0.44 Mil) and increased from Jun. 2024 (C$0.44 Mil) to Sep. 2024 (C$0.44 Mil).

Biocure Technology's annual Total Liabilities declined from Dec. 2021 (C$5.01 Mil) to Dec. 2022 (C$4.41 Mil) and declined from Dec. 2022 (C$4.41 Mil) to Dec. 2023 (C$0.37 Mil).

Biocure Technology Total Liabilities Historical Data

The historical data trend for Biocure Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Total Liabilities Chart

Biocure Technology Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4.99

6.87

5.01

4.41

0.37

Biocure Technology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															0.91	0.37	0.40	0.44	0.44

Biocure Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biocure Technology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.331	+	(0.042	+	-2.0816681711722E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.37

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1.976	-	1.603
	=	0.37

Biocure Technology's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.394	+	(0.048	+	-1.3877787807814E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.44

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	1.992	-	1.55
	=	0.44

Biocure Technology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocure Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BICTF:USA 1WH0:Germany

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9

Website

https://www.biocuretech.com

Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.

Executives

Konstantin Lichtenwald

Director, Senior Officer